Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04074616 · ClinicalTrials.gov registry record · NA

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation

A NA study of Neurogenic Bladder and Chronic Spinal Cord Injury, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT04074616 is a NA study of Neurogenic Bladder and Chronic Spinal Cord Injury that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 50 participants, below the 90-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04074616, a NA study of Neurogenic Bladder and Chronic Spinal Cord Injury, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home

Interventions

  • DEVICE High Dose
  • DEVICE Low dose

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2019-11-19
Est. Completion 2023-04-20
Phase NA

What the Registry Record Tells You About NCT04074616

The ClinicalTrials.gov registry entry for NCT04074616 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (44% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neurogenic Bladder appearing as the primary indexed condition, and to 2 interventions - of which High Dose is the first listed.

NCT04074616 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04074616 about?

NCT04074616 is a clinical study titled "Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation". The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home

What is the current status of trial NCT04074616?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2019-11-19. Estimated completion is 2023-04-20.

What conditions does trial NCT04074616 study?

This clinical trial studies the following conditions: Neurogenic Bladder, Chronic Spinal Cord Injury.

What interventions are being tested in trial NCT04074616?

The interventions under investigation include: High Dose (DEVICE), Low dose (DEVICE).

Who is sponsoring clinical trial NCT04074616?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04074616 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurogenic Bladder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.